DRUG Bright Minds Biosciences, Inc.
Biotechnology NasdaqCM
Trading Signals (DRUG)
Overall Signal
BUY
Strong buyish signal based on multiple indicators.
Key Price Levels
Support Levels
- Strong Support $25.5
- Medium Support $28.25
- Weak Support $31.01
Resistance Levels
- Weak Resistance $36.53
- Medium Resistance $39.29
- Strong Resistance $42.04
Stop Loss Suggestions
- Conservative $27.47
- Moderate $29.63
- Aggressive $26.88
Analyst Ratings
Current Rating
Signal Indicator
| Indicator | Signal | Strength | Timeframe |
|---|---|---|---|
| Moving Averages | BUY |
|
Short & Medium Term |
| Oscillators | BUY |
|
Short Term |
| Trend Indicators | BUY |
|
Medium Term |
| Volume Indicators | BUY |
|
Short & Medium Term |
| Support/Resistance | NEUTRAL |
|
Short Term |
Stock Price Prediction Price Target Probabilities (DRUG)
Quarterly Outlook :
2026-11-04
Bullish Scenario
from current 33.83%
Strong upward momentum and confirmed bullish trend, with potential for significant price appreciation. Indicators point to sustained buying pressure. ADX (18.09) indicates a weak or ranging trend. Market is likely in a consolidation or range-bound phase. RSI (54.37) is in bullish territory, indicating upward momentum. MACD line (0.69) is above Signal line (0.08) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 4.57, indicating the average weekly price range.
2026-11-04
Base Scenario
from current 8.12%
Price is likely to continue its moderate trajectory, reflecting underlying market conditions and historical volatility. Indicators suggest a balanced outlook. ADX (18.09) indicates a weak or ranging trend. Market is likely in a consolidation or range-bound phase. RSI (54.37) is in bullish territory, indicating upward momentum. MACD line (0.69) is above Signal line (0.08) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 4.57, indicating the average weekly price range.
2026-11-04
Bearish Scenario
from current -27.07%
Increased selling pressure and potential for a significant price correction or downtrend. Indicators suggest waning bullish momentum or strengthening bearish forces. ADX (18.09) indicates a weak or ranging trend. Market is likely in a consolidation or range-bound phase. RSI (54.37) is in bullish territory, indicating upward momentum. MACD line (0.69) is above Signal line (0.08) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 4.57, indicating the average weekly price range.
Annual Outlook
2026-11-04
Bullish Scenario
from current 67.66%
Long-term bullish trend with strong fundamental catalysts and sustained institutional buying. Expect significant capital appreciation over the year. ADX (18.09) indicates a weak or ranging trend. Market is likely in a consolidation or range-bound phase. RSI (54.37) is in bullish territory, indicating upward momentum. MACD line (0.69) is above Signal line (0.08) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 4.57, indicating the average weekly price range.
2026-11-04
Base Scenario
from current 16.24%
Steady long-term growth consistent with market and industry averages. Price expected to follow a typical growth trajectory. ADX (18.09) indicates a weak or ranging trend. Market is likely in a consolidation or range-bound phase. RSI (54.37) is in bullish territory, indicating upward momentum. MACD line (0.69) is above Signal line (0.08) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 4.57, indicating the average weekly price range.
2026-11-04
Bearish Scenario
from current -54.13%
Long-term bearish trend with significant headwinds from economic factors, industry disruption, or company-specific issues. Expect notable price depreciation. ADX (18.09) indicates a weak or ranging trend. Market is likely in a consolidation or range-bound phase. RSI (54.37) is in bullish territory, indicating upward momentum. MACD line (0.69) is above Signal line (0.08) (bullish crossover), confirming upward momentum. Both lines are above zero, reinforcing bullish trend. Current Weekly ATR is 4.57, indicating the average weekly price range.
Technical Analysis (DRUG)
Trend Identification
EMA
Exponential Moving Average
Current price (33.77) is above both Short MA (28.64) and Long MA (28.68). This indicates strong bullish momentum. Short MA (28.64) is below Long MA (28.68), a bearish crossover ('Death Cross' if it's a significant period). This indicates a downward trend. MAs (28.64, 28.68, 30.52) show mixed alignment, suggesting market indecision or range-bound activity.
MACD
Moving Average Convergence Divergence
MACD line is above the Signal line (bullish crossover). This indicates upward momentum. Histogram (0.9300) is positive and expanding, confirming bullish momentum. Both MACD and Signal lines are above the zero line, reinforcing bullish momentum (bullish territory). This is a strong buy signal. Consider long positions.
ADX
Average Directional Index
ADX (28.20) indicates a strong trend is present. +DI (35.36) is above -DI (13.39), suggesting a bullish directional bias. This combination points to a strong upward trend. Consider taking long positions, as the strong upward trend is confirmed.
Momentum Measurement
RSI (2026-11-04)
Relative Strength Index
RSI (65.02) is in the bullish territory, but not yet overbought. This indicates upward momentum. Monitor for continuation or signs of weakness.
OBV (2026-11-04)
On-Balance Volume
OBV (138710797.00) is rising, indicating buying pressure and accumulation. Price is rising and OBV is rising. This is bullish confirmation, indicating buying pressure supports the price increase. Consider holding long positions or initiating new ones. Volume is supporting the trend.
Stochastic (2026-11-04)
Stochastic Oscillator
Stochastics (%K: 54.10, %D: 64.91) are in the neutral zone (between 20 and 80). A bearish crossover (%K below %D) is observed, potentially signaling a downward trend reversal or continuation. Stronger signal if this occurs above 50.
CCI (2026-11-04)
Commodity Channel Index
CCI (67.80) is between 0 and +100. This indicates bullish momentum is present, but not yet extreme. A move above 0 from negative territory (bullish zero-line cross) can indicate a potential buy signal.
Volatility Measurement
ATR (2026-11-04)
Average True Range
Current ATR is 2.3000. ATR indicates average volatility. Market conditions are relatively stable.
Bollinger Bands (2026-11-04)
Volatility Bands
Current price (33.77) is within the Bollinger Bands (21.23 - 36.06). This suggests the price is trading within its typical volatility range. Price is above the Middle Band (28.64), indicating short-term bullish bias. Bollinger Bands are wide. This indicates high volatility. Prices tend to revert to the mean after extended periods of high volatility.
Risk Management & Potential Reversals (DRUG)
SAR (2026-11-04)
Parabolic Stop and Reverse
SAR points below price indicate bullish trend. Current SAR at 27.47 is 18.66% from price. Consider SAR as a potential stop-loss level to protect gains in an uptrend.
Stochastic (2026-11-04)
Neutral
Stochastic is in neutral territory (54.1). No clear overbought/oversold signal. Current crossover status: Bearish.
RSI (2026-11-04)
Reversal Perspective
Current RSI level is in neutral territory. No RSI divergence detected. Current RSI level doesn't suggest imminent reversal.
Bollinger Bands (2026-11-04)
Reversal Perspective
Bollinger Bands are widening, indicating high volatility and potential strong trend continuation.Price is in the upper half of the bands, suggesting a bullish bias.No indication of imminent volatility expansion or reversal.
Holder List Top 20 (DRUG)
| Holder Name | Holder Type | Shares | Pct. Held | Date Reported |
|---|---|---|---|---|
| Janus Henderson Group PLC | INSTITUTIONAL | 1111368 | 15.78% | 2025-03-31 |
| Cormorant Asset Management, LP | INSTITUTIONAL | 1059331 | 15.04% | 2025-03-31 |
| Sio Capital Management, LLC | INSTITUTIONAL | 507562 | 7.21% | 2025-03-31 |
| Commodore Capital Lp | INSTITUTIONAL | 500000 | 7.1% | 2025-03-31 |
| Perceptive Advisors Llc | INSTITUTIONAL | 444649 | 6.31% | 2025-03-31 |
| Vivo Capital, LLC | INSTITUTIONAL | 251572 | 3.57% | 2025-03-31 |
| RA Capital Management, L.P. | INSTITUTIONAL | 206427 | 2.93% | 2025-03-31 |
| Adage Capital Partners GP L.L.C. | INSTITUTIONAL | 200000 | 2.84% | 2025-03-31 |
| Millennium Management Llc | INSTITUTIONAL | 192557 | 2.73% | 2025-03-31 |
| Morgan Stanley | INSTITUTIONAL | 156550 | 2.22% | 2025-03-31 |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | MUTUALFUND | 14481 | 0.21% | 2025-05-31 |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | MUTUALFUND | 3337 | 0.05% | 2025-04-30 |
| iShares Trust-iShares Neuroscience and Healthcare ETF | MUTUALFUND | 550 | 0.01% | 2025-04-30 |
| ProShares Trust-ProShares Ultra Russell2000 | MUTUALFUND | 465 | 0.01% | 2025-06-30 |
| ProShares Trust-ProShares UltraPro Russell2000 | MUTUALFUND | 386 | 0.01% | 2025-06-30 |
| ProShares Trust-ProShares Russell 2000 High Income ETF | MUTUALFUND | 78 | 0% | 2025-06-30 |
| ProShares Trust-ProShares Hedge Replication ETF | MUTUALFUND | 6 | 0% | 2025-06-30 |
| insidersPercentHeld | MAJOR | 0% | ||
| institutionsPercentHeld | MAJOR | 0% | ||
| institutionsFloatPercentHeld | MAJOR | 0% |